Merakris Therapeutics Spotlights Investigational New Drug, MTX-001, with Innovation Showcase Win at 2025 Advanced Wound Care Summit
MTX-001 recognized for its clinical and commercial potential for treating chronic non-healing venous leg ulcers (VLUs)
RESEARCH TRIANGLE PARK, N.C., July 24, 2025 (GLOBE NEWSWIRE) -- Merakris Therapeutics announces it was selected as the winner of the 2025 Innovation Showcase at the Advanced Wound Care (AWC) Summit held last week in Boston. The award recognizes the most promising early-stage disruptive technology in wound care.
During the showcase, Merakris CEO Chris Broderick presented MTX-001, a first-in-class injectable biologic drug therapy derived from purified amniotic fluid for the treatment of non-healing venous leg ulcers (VLUs) including:
- Total Addressable Market (TAM)/market opportunity & payer strategy
- Key findings from ongoing Phase 2 clinical trial of investigational new drug MTX-001
- Mechanisms of action
- Production scale manufacturing plan
A panel of industry experts selected Merakris for the award based on several criteria including clinical innovation, therapeutic potential, commercialization strategy, and overall impact on the wound care landscape.
“Standard therapies continue to fail many patients suffering from non-healing VLUs,” said Broderick. “Merakris is pioneering MTX-001 and developing a new class of regenerative biologics that address chronic wound closure. We’re honored to be recognized by the AWC Summit for our work to advance care in this underserved patient population.”
For strategic partnership and collaboration opportunities, please visit https://merakris.com/partnerships.
For more information about the MTX-001 clinical trial or Merakris’ Expanded Access Program, please contact medaffairs@merakris.com.
About Merakris Therapeutics
Merakris Therapeutics is a leading innovator in regenerative medicine focused on developing and commercializing biologically derived products for wound healing and other complex conditions. Leveraging advanced biologic manufacturing capabilities and a robust research pipeline, Merakris is committed to improving patient outcomes and advancing the science of regenerative therapies.
Merakris Forward Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of Merakris’ products, or regarding potential future revenues from any such product. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Merakris’ management believes that any forward-looking statements in this press release are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Merakris, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and advisors and on the global economy as a whole. Investigational drug tradename (Dermacyte Liquid or Dermacyte Amniotic Wound Care Liquid) has not been approved by FDA.
Contact Michelle Murray michelle@yourfractionalcmo.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
